CHD-related catheterization

Slides:

Advertisements

Similar presentations

British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.

Advertisements

Optimal Management of ACS Invasive vs Conservative Strategy

Results Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. N Eng J Med August 31. DOI: /NEJMoa

Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just.

1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.

Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.

1 Journal meeting with EMB 急診室的如臨大敵 STEMI ER 陳莉瑋醫師.

Quality Improvement Initiatives. National Service Framework for Coronary Heart Disease-UK Cooperative Cardiovascular Project (CCP)-USA National Registry.

ACUTE CORONARY SYNDORME Mostafa alshamiri January 2013.

Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.

Presenter Disclosure Information DISCLOSURE INFORMATION: The following relationships exist related to this presentation Stock options None; Consults for.

SPACE The Saudi Project for Assessment of Coronary Events A registry database of patients with ACS. A registry database of patients with ACS. Provides.

The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,

Implementation of a Sensitive Troponin I Assay and Risk of Recurrent Myocardial Infarction and Death in Patients With Suspected Acute Coronary Syndrome.

The Impact of For-Profit Hospital Status on the Care and Outcomes of Patients with NSTEMI: Results From CRUSADE Bimal R. Shah, MD, Seth W. Glickman, MD,

Date of download: 5/28/2016 From: Optimal Timing of Coronary Invasive Strategy in Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Review.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Relationship Between Operator Volume and Adverse.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Cardiovascular Imaging Research at the Crossroads.

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.

Date of download: 7/5/2016 From: Validation of the Appropriate Use Criteria for Coronary Angiography: A Cohort Study Ann Intern Med. 2015;162(8):

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Value of Platelet Reactivity in Predicting Response.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Comprehensive Meta-Analysis of Safety and Efficacy.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

From: Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data.

Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.

From: Bivalirudin Versus Heparin With or Without Glycoprotein IIb/IIIa Inhibitors in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention:

Atherosclerotic Cardiovascular Heart Disease in Women

Associate Professor, Honorary Consultant Cardiologist

Figure 2 Kaplan–Meier estimates of event-free survival (survival to the combined endpoint). From: Long-term outcomes of patients with acute myocardial.

Clinical need for determination of vulnerable plaques

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Initial pharmacotherapy for ST-segment elevation myocardial infarction

Gender Disparity in Treatment of Coronary Artery Disease?

Abela M, Lentini F, Gatt A, Felice Malta Medial School Conference 2012

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Chapter 28 Management of Patients With Coronary Vascular Disorders

The following slides are based on a presentation at a Satellite Symposium in association with the Annual Cardiovascular Conference at Lake Louise, Alberta,

Section F: Clinical guidelines

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Cost-Effectiveness of Introducing Point-of-Care Test for Detection of Level of Glycogen Phosphorylase in Early Diagnostic Algorithm of Acute Coronary.

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

% Heparin + GPI IIb/IIIa Bivalirudin +

Figure 2 Absolute difference in seasonal peak

Figure 4 Observational studies on multiple treatment strategies

Category: PCI Research

Global Registry of Acute Coronary Events: GRACE

Nat. Rev. Cardiol. doi: /nrcardio

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Tornado diagram of one-way deterministic sensitivity analysis.

Fig. 3. Determining factors of the proportion of class C in the hospital. (A) Relationship between the proportion of class C cases and the number of PCIs.

Institute of Cardiology

ARISE Trial Aggressive Reduction of Inflammation Stops Events

Nat. Rev. Cardiol. doi: /nrcardio

SOLID-TIMI 52 Trial design: Participants within 30 days of an acute coronary syndrome (ACS) were randomized to darapladib 160 mg daily (n = 6,504) versus.

Markov model scheme. Markov model scheme. Patients start (state 0) with uncomplicated PCI revascularisation; then cycle between health states until death.

The American College of Cardiology Presented by Dr. A. Abazid

C-3. Clinical trial updates: GP IIb/IIIa inhibitors

Leslee J. Shaw et al. JIMG 2010;3:

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Major bleeding with bivalirudin versus unfractionated heparin (UFH) in predominantly non-ST segment elevation acute coronary syndrome (NSTE-ACS) studies;

Section C: Clinical trial update: Oral antiplatelet therapy

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.

Performance of the Manchester Acute Coronary Syndromes decision rule in the validation study. Performance of the Manchester Acute Coronary Syndromes decision.

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Cardiovascular Epidemiology and Epidemiological Modelling

Many post-MI patients are not receiving optimal therapy

Presentation transcript:

CHD-related catheterization A. Epidemiology Update CHD-related catheterization Content Points: There are an estimated 12,900,000 patients with coronary heart disease (CHD) in this country.1 The symptomatic manifestations of this disease-myocardial infarction (MI) and angina-afflict 7,600,000 and 6,600,000 individuals, respectively. In 2000, CHD accounted for 1,318,000 diagnostic cardiac catheterization procedures, making it the most common cardiovascular inpatient procedure in the United States. 1 American Heart Association. Heart Disease and Stroke Statistics-2003 Update. Dallas, Tex: American Heart Association; 2002.

Global variation in hospital management of ACS Content Points: The Global Registry of Acute Coronary Events (GRACE) study found marked geographic variations in antithrombotic and interventional strategies for management of acute coronary syndromes (ACS).1 Use of percutaneous coronary intervention (PCI) and glycoprotein (GP) IIb/IIIa inhibitors is relatively higher in the United States compared with other geographic regions. In contrast, use of low-molecular-weight heparin (LMWH) is much lower compared with other regions. As shown herein, data support an expanded role for LMWH in ACS in the United States, particularly in the setting of PCI. 1 Fox KAA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome. Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2002;23:1177-1189.